Chattanooga's Program in Women's Oncology
Chattanooga, Tennessee, United States
Oncologist in Chattanooga, Tennessee
102 Central Ave, Chattanooga, TN 37403
About Chattanooga's Program in Women's Oncology
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Gynecologic Oncology Group
7
GOG Foundation
4
Morphotek
2
National Cancer Institute (NCI)
2
Accelerated Community Oncology Research Network
1
Agenus Inc.
1
Akeso
1
Aravive, Inc.
1
Astellas Pharma Global Development, Inc.
1
CTI BioPharma
1
Ciphergen Biosystems
1
Clinical Trials at Chattanooga's Program in Women's Oncology
During the past decade, Chattanooga's Program in Women's Oncology conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 11 clinical trials were completed, i.e. on
average, 157.1% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 6 clinical trials were completed. i.e. 150%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
2003-08-25
2021-01-05
Completed
1,381
Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels
2004-05-01
2006-12-01
Completed
60
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
2004-12-01
2008-07-01
Completed
244
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
2005-03-21
2022-02-22
Active, not recruiting
1,157
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
2006-02-01
2010-08-01
Terminated
402
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
2005-09-01
2015-04-01
Completed
1,873
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Chattanooga's Program in Women's Oncology" #1 sponsor was "Gynecologic Oncology Group" with 7 trials, followed by "GOG Foundation" with 4 trials
sponsored, "Morphotek" with 2 trials sponsored, "National Cancer Institute (NCI)" with 2 trials sponsored and "Accelerated Community Oncology Research Network"
with 2 trials sponsored. Other sponsors include 12 different institutions and
companies that sponsored additional 22 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Chattanooga's Program in Women's Oncology"
#1 collaborator was "National Cancer Institute (NCI)" with 10 trials as a collaborator, "Advanced Clinical Research Services, LLC" with 1 trials as a collaborator, "Akesobio Australia Pty Ltd" with 1 trials as a collaborator, "Celgene Corporation" with 1 trials as a collaborator and "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were
collaborators in the rest 14 trials.
Clinical Trials Conditions at Chattanooga's Program in Women's Oncology
According to Clinical.Site data, the most researched conditions in "Chattanooga's Program in Women's Oncology" are
"Ovarian Cancer" (8 trials), "Fallopian Tube Cancer" (4 trials), "Cervical Cancer" (3 trials), "Endometrial Clear Cell Adenocarcinoma" (3 trials) and "Endometrial Serous Adenocarcinoma" (3 trials). Many other conditions were trialed in "Chattanooga's Program in Women's Oncology" in a lesser frequency.
Clinical Trials Intervention Types at Chattanooga's Program in Women's Oncology
Most popular intervention types in "Chattanooga's Program in Women's Oncology" are "Drug" (25 trials), "Other" (12 trials), "Biological" (4 trials), "Procedure" (3 trials) and "Radiation" (3 trials). Other intervention types were less common.
The name of intervention was led by "Laboratory Biomarker Analysis" (8 trials), "Paclitaxel" (8 trials), "Quality-of-Life Assessment" (8 trials), "Carboplatin" (6 trials) and "Questionnaire Administration" (4 trials). Other intervention names were less common.
Clinical Trials Genders at Chattanooga's Program in Women's Oncology
The vast majority of trials in "Chattanooga's Program in Women's Oncology" are
32 trials for "Female" genders and 1 trials for "All" genders.
Clinical Trials Status at Chattanooga's Program in Women's Oncology
Currently, there are NaN active trials in "Chattanooga's Program in Women's Oncology".
undefined are not yet recruiting,
2 are recruiting,
5 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 18 completed trials in Chattanooga's Program in Women's Oncology,
undefined suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Chattanooga's Program in Women's Oncology, 3 "Phase 1"
clinical trials were conducted, 12 "Phase 2" clinical
trials and 15 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 2 trials that are defined as “Not Applicable".